Amgen Inc. Investment Income, Interest
Amgen Inc. (AMGN) reported Investment Income, Interest of $125.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Amgen Inc. investment income, interest for the quarter ending 2026-06-30 was $125.00M, a 45.35% increase year-over-year.
- Amgen Inc. investment income, interest for the quarter ending 2026-03-31 was $101.00M, a 19.84% decline year-over-year.
- Amgen Inc. investment income, interest for the quarter ending 2025-12-31 was $97.00M, a 16.38% decline year-over-year.
- Amgen Inc. investment income, interest for the quarter ending 2025-09-30 was $99.00M, a 21.43% decline year-over-year.
- Amgen Inc. investment income, interest for fiscal 2025 was $408.00M, a 20.00% decline from fiscal 2024.
- Amgen Inc. investment income, interest for fiscal 2024 was $510.00M, a 57.50% decline from fiscal 2023.
- Amgen Inc. investment income, interest for fiscal 2023 was $1.20B, a 844.88% increase from fiscal 2022.
- Amgen Inc. investment income, interest for fiscal 2022 was $127.00M, a 1054.55% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $125.00M 10-Q · filed 2026-08-05 | $226.00M 10-Q · filed 2026-08-05 | $323.00M derived: sum of 3 quarters · filed 2026-08-05 | $422.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $101.00M 10-Q · filed 2026-05-01 | $198.00M derived: sum of 2 quarters · filed 2026-05-01 | $297.00M derived: sum of 3 quarters · filed 2026-05-01 | $383.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $97.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $196.00M derived: sum of 2 quarters · filed 2026-02-13 | $282.00M derived: sum of 3 quarters · filed 2026-08-05 | $408.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $99.00M 10-Q · filed 2025-11-05 | $185.00M derived: sum of 2 quarters · filed 2026-08-05 | $311.00M 10-Q · filed 2025-11-05 | $427.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $86.00M 10-Q · filed 2026-08-05 | $212.00M 10-Q · filed 2026-08-05 | $328.00M derived: sum of 3 quarters · filed 2026-08-05 | $454.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $126.00M 10-Q · filed 2026-05-01 | $242.00M derived: sum of 2 quarters · filed 2026-05-01 | $368.00M derived: sum of 3 quarters · filed 2026-05-01 | $483.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $116.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $242.00M derived: sum of 2 quarters · filed 2026-02-13 | $357.00M derived: sum of 3 quarters · filed 2026-02-13 | $510.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $126.00M 10-Q · filed 2025-11-05 | $241.00M derived: sum of 2 quarters · filed 2025-11-05 | $394.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $115.00M 10-Q · filed 2025-08-06 | $268.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $153.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $1.20B 10-K · filed 2026-02-13 | |||
| 2022-12-31 | $127.00M 10-K · filed 2025-02-14 | |||
| 2021-12-31 | $11.00M 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |